Identification of novel small molecule inhibitors of activated protein C.

[1]  H C Hemker,et al.  The role of phospholipids and factor Va in the prothrombinase complex. , 1980, The Journal of biological chemistry.

[2]  J. Griffin,et al.  Deficiency of protein C in congenital thrombotic disease. , 1981, The Journal of clinical investigation.

[3]  R. Marlar,et al.  Neonatal Purpura Fulminans Due to Homozygous Protein C or Protein S Deficiencies , 1990, Seminars in thrombosis and hemostasis.

[4]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Tulinsky,et al.  The structure of alpha-thrombin inhibited by a 15-mer single-stranded DNA aptamer. , 1994, The Journal of biological chemistry.

[6]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[7]  K. Preissner,et al.  Calcium-Dependent Activation of Protein C by Thrombin/Thrombomudulin: Role of Negatively Charged Amino Acids within the Activation Peptide of Protein C , 1994, Thrombosis and Haemostasis.

[8]  B. Dahlbäck,et al.  Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. , 1994, The Journal of biological chemistry.

[9]  B. Dahlbäck,et al.  Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Hemker,et al.  Peptide Bond Cleavages and Loss of Functional Activity during Inactivation of Factor Va and Factor VaR506Q by Activated Protein C (*) , 1995, The Journal of Biological Chemistry.

[11]  H. Hemker,et al.  A Prothrombinase-based Assay for Detection of Resistance to Activated Protein C , 1996, Thrombosis and Haemostasis.

[12]  F. España,et al.  Quantification of Circulating Activated Protein C in Human Plasma by Immunoassays - Enzyme Levels are Proportional to Total Protein C Levels , 1996, Thrombosis and Haemostasis.

[13]  R. Kaufman,et al.  Moderation of hemophilia A phenotype by the factor V R506Q mutation. , 1996, Blood.

[14]  S Foundling,et al.  The 2.8 A crystal structure of Gla‐domainless activated protein C. , 1996, The EMBO journal.

[15]  K. Mann,et al.  Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. , 1996, Blood.

[16]  K. Mann,et al.  An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). , 1997, Blood.

[17]  P. Urvil,et al.  Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function , 1998 .

[18]  B. Dahlbäck,et al.  Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. , 1999, Biochemistry.

[19]  M. Dwyer,et al.  Peptide exosite inhibitors of factor VIIa as anticoagulants , 2000, Nature.

[20]  B. Ritchie,et al.  Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A , 2000, Thrombosis and Haemostasis.

[21]  The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. , 2000 .

[22]  F. Church,et al.  Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin , 2000, FEBS letters.

[23]  B. Dahlbäck,et al.  Secondary Substrate-binding Exosite in the Serine Protease Domain of Activated Protein C Important for Cleavage at Arg-506 but Not at Arg-306 in Factor Va* , 2001, The Journal of Biological Chemistry.

[24]  J. Griffin,et al.  Molecular Characterization of an Extended Binding Site for Coagulation Factor Va in the Positive Exosite of Activated Protein C* , 2002, The Journal of Biological Chemistry.

[25]  A. Rezaie,et al.  Contribution of basic residues of the 70-80-loop to heparin binding and anticoagulant function of activated protein C. , 2002, Biochemistry.

[26]  B. Dahlbäck,et al.  Congenital and acquired activated protein C resistance. , 2003, Seminars in vascular medicine.

[27]  B. Dahlbäck,et al.  Gla domain-mutated human protein C exhibiting enhanced anticoagulant activity and increased phospholipid binding. , 2003, Blood.

[28]  B. Dahlbäck,et al.  Altered inactivation pathway of factor Va by activated protein C in the presence of heparin. , 2004, European journal of biochemistry.

[29]  K. Mertens,et al.  Does activated protein C‐resistant factor V contribute to thrombin generation in hemophilic plasma? , 2005, Journal of thrombosis and haemostasis : JTH.

[30]  M. Poncz,et al.  Factor V Leiden improves in vivo hemostasis in murine hemophilia models , 2005, Journal of thrombosis and haemostasis : JTH.

[31]  H. Hemker,et al.  Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders. , 2006, Journal of medicinal chemistry.

[32]  T. Orfeo,et al.  Peptidomimetic inhibitors for activated protein C: implications for hemophilia management , 2006, Journal of thrombosis and haemostasis : JTH.

[33]  E. Persson,et al.  Inhibitors of factor VIIa affect the interface between the protease domain and tissue factor. , 2006, Biochemical and biophysical research communications.

[34]  H. Hemker,et al.  Thrombin generation, a function test of the haemostaticthrombotic system , 2006, Thrombosis and Haemostasis.

[35]  Ajay N. Jain.  Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..

[36]  Jacques Chomilier,et al.  Frog: a FRee Online druG 3D conformation generator , 2007, Nucleic Acids Res..

[37]  José A Fernández,et al.  Activated protein C , 2007, Journal of thrombosis and haemostasis : JTH.

[38]  A. Tulinsky,et al.  Intermolecular interactions and characterization of the novel factor Xa exosite involved in macromolecular recognition and inhibition: crystal structure of human Gla-domainless factor Xa complexed with the anticoagulant protein NAPc2 from the hematophagous nematode Ancylostoma caninum. , 2007, Journal of molecular biology.

[39]  J. Griffin,et al.  The cytoprotective protein C pathway. , 2007, Blood.

[40]  B. Dahlbäck,et al.  Identification of Surface Epitopes of Human Coagulation Factor Va That Are Important for Interaction with Activated Protein C and Heparin* , 2008, Journal of Biological Chemistry.

[41]  Bingding Huang,et al.  MetaPocket: a meta approach to improve protein ligand binding site prediction. , 2009, Omics : a journal of integrative biology.

[42]  T. Madhusudhan,et al.  An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. , 2009, Chemistry & biology.

[43]  B. Dahlbäck,et al.  Inhibition of Thrombin Formation by Active Site Mutated (S360A) Activated Protein C* , 2010, The Journal of Biological Chemistry.

[44]  E. Lutgens,et al.  The structure-function relationship of activated protein C , 2011, Thrombosis and Haemostasis.

[45]  A. Gale,et al.  Function of the activated protein C (APC) autolysis loop in activated FVIII inactivation , 2011, British journal of haematology.

[46]  Dima Kozakov,et al.  BIOINFORMATICS APPLICATIONS NOTE , 2022 .

[47]  Daniel Kuhn,et al.  DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment , 2012, Bioinform..

[48]  J. Griffin,et al.  Protein C anticoagulant and cytoprotective pathways , 2012, International Journal of Hematology.

[49]  P. Fay,et al.  Variable contributions of basic residues forming an APC exosite in the binding and inactivation of factor VIIIa. , 2013, Biochemistry.